Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast Cancer

Video

Ingrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

Ingrid A. Mayer, MD, co-leader and clinical director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, associate professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

In the early setting, targeted therapies are being incorporated in both the adjuvant and neoadjuvant settings, says Mayer. There are several trials ongoing and being planned utilizing CDK4/6 inhibitors, as well as everolimus. If these trials end up showing a survival advantage, it would revolutionize the way patients with ER-positive breast cancer are treated, she says.

In the metastatic setting, there are also numerous targeted therapies being investigated including CDK4/6 inhibitors, PI3-kinase inhibitors, histone deacetylase inhibitors, EGFR inhibitors, and more. Patient selection is going to be one of the biggest challenges, says Mayer. Instead of large trials, studies may need to be smaller and more specific going forward.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS